3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
4
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
23
Colonic Neoplasms
16
Colorectal Neoplasms
14
Breast Neoplasms
11
Stomach Neoplasms
5
Pancreatic Neoplasms
5
Bile Duct Neoplasms
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Squamous Cell Carcinoma of Head and Neck
3
Liver Neoplasms
3
Gallbladder Neoplasms
3
Breast Neoplasms, Male
3
Neoplasm Metastasis
2
Inflammatory Breast Neoplasms
2
Head and Neck Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Biliary Tract Neoplasms
2
Waldenstrom Macroglobulinemia
1
Turcot syndrome
1
Somatostatinoma
1
Sezary Syndrome
1
Salivary Gland Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
dehydroftorafur
2
Leucovorin
2
Fluorouracil
2
trametinib
1
binimetinib
1
Specimen Handling
1
Sorafenib
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Erlotinib Hydrochloride
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NIH
×
Klatskin Tumor
×
Capecitabine
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts